Janssen Presents P-IIb (QUASAR) Induction Study Results of Tremfya (guselkumab) for Active Ulcerative Colitis at ACG 2022
Shots:
- The P-IIb (QUASAR) induction dose-ranging study evaluating Tremfya in 313 adults with moderately to severely active UC with inadequate response/intolerance to conventional therapies and advanced therapies
- The results showed that 80.2% of patients were randomized to Tremfya (200mg, IV) arm & 78.5% with 400mg achieved a clinical response of @12 or 24wks., and 52.1% did not achieve a clinical response @12wk. were switched to Tremfya (SC) & achieved clinical response @24wk., 54.3% & 50.0% achieved clinical response @24wk. who previously received induction Tremfya (200 or 400mg, IV) respectively
- The safety findings @24wk. were consistent with that @12wk. with the known safety profile for Tremfya in approved indications & no new safety concerns were seen
Ref: Janssen | Image: Janssen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
